BPC-157 10mg
99.2% HPLC PurityA 15-amino-acid peptide derived from gastric juice, studied in tissue repair and gut research.

SKU: PCUK-TB10 • Batch: 100272
Synthetic version of Thymosin Beta-4, studied for tissue repair, angiogenesis and recovery research. 10mg lyophilised vial, 99.205% HPLC purity, independently verified.
Read the full description ↓Price includes GST
✓Free shipping on orders over $250 AUD
✓Australia Post tracked — Standard $12.99 / Express $18.99
✓Dispatched next business day (orders before 11PM AEST)
A 15-amino-acid peptide derived from gastric juice, studied in tissue repair and gut research.
A GHRH analogue paired with a GHRP in one vial, studied in growth-hormone research.
Sterile water with 0.9% benzyl alcohol, used to reconstitute lyophilised peptides.
Purity independently verified at a leading Australian university via HPLC & mass spectrometry.
TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4 (Tβ4), a 43-residue peptide involved in actin regulation, cell migration, and tissue repair pathways. Supplied as a lyophilised powder at 99.205% HPLC purity with full Certificate of Analysis (COA) documentation.
TB-500 is synthesised at our own facility here in Australia under GMP-compliant conditions — chain-of-custody stays unbroken from raw material to dispatch. An independent third-party laboratory confirms HPLC purity, mass spectrometry identity, LAL endotoxin levels (<1.0 EU/mg) and sterility on every batch.
Research has explored TB-500's role in angiogenesis, cell migration, wound healing, and recovery models, where its actin-binding activity is a primary area of investigation. Strictly for in-vitro laboratory research only.
TB-500 is a synthetic form of Thymosin Beta-4, studied in preclinical research for its role in actin regulation, cell migration, angiogenesis, and tissue-repair pathways. All use is strictly for in-vitro laboratory research only.
Our TB-500 10mg is independently verified at 99.205% HPLC purity. Each batch is tested by an accredited third-party laboratory and ships with a full Certificate of Analysis (COA).
Store lyophilised TB-500 at −20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 4 weeks. Avoid repeated freeze-thaw cycles.
Add bacteriostatic water (BAC water) slowly to the vial at a 1–2mL volume. Gently swirl; do not shake. Allow the powder to dissolve completely before use in research protocols.
Yes. TB-500 is legal to purchase in Australia for legitimate in-vitro laboratory and research purposes. It is not approved for human consumption or therapeutic use.
TB-500 10mg is sold strictly for in-vitro laboratory and research purposes only. This product is not intended for human consumption, therapeutic use, cosmetic use, or veterinary application. It has not been evaluated by the Therapeutic Goods Administration (TGA) or any other regulatory body for human use. You must be 18 years of age or older to purchase. By purchasing, you confirm that you are a qualified researcher and will use this product in compliance with all applicable Australian laws and regulations.
No questions yet — be the first to ask about this product.
Recent peer-reviewed studies from PubMed related to TB-500. Provided for research context — not medical advice.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, Awan TM · Sports medicine (Auckland, N.Z.) · 2026
PMID: 41966639
Peptide Supplements and Their Therapeutic Applications in Sports Medicine
Tewari K, Liu TP, Im C, et al. · The American journal of sports medicine · 2026
PMID: 42578445
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential
Esposito S, Deventer K, Goeman J, et al. · Drug testing and analysis · 2012
PMID: 22962027
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management
Luansritisakul C, Chiang MC, Burns SL, et al. · Current pain and headache reports · 2026
PMID: 42635865
Source: U.S. National Library of Medicine (PubMed). Citations are fetched live and cached; inclusion does not imply endorsement of any therapeutic use.